Comprehensive LungSEQPlus Panel : 1016995

Message

Please provide most recent Pathology report.

Test Code

MDFCPNGS50LP or 106995

Alias/See Also

LungSeq; Non Small Cell Lung Cancer; LungSeq by NGS, TMB, PD-L1, MET

CPT Codes
81445, 88271x2, 88275, 88360, 81479

Includes

LUNGSEQ PLUS Panel Components: PDL1; MET by FISH; AKT1; ALK; APC; ATM; BRAF; CDH1; CDKN2A; CSF1R; CTNNB1; EGFR; ERBB2; ERBB4; ESR1; FBXW7; FGFR1; FGFR2; FGFR3; FLT3; GNA11; GNAQ; GNAS; HNF1A; HRAS; IDH1; IDH2; JAK2; JAK3; KDR; KIT; KRAS; MAPD2K1; MET; MLH1; NOTCH1; NRAS; PDGFRA; PIK3CA; PIK3R1; PTEN; PTPN11; RB1; RET; ROS1; SMAD4; SMARCB1; SMO; SRC; STK11; TP53; VHL; TMB; ALK fusion; NTRK 1,2,3 fusion; RET fusion; ROS1 fusion; METex14 skip

Instructions

Tissue.

Transport Container

Paraffin embedded Tissue accompanied by a circled H & E slide indicating the area to be examined: submit in sterile biohazard plastic bag. Slides: submit 24 FFPE slides and 1 H & E slide (or one additonal slide) in slide holder. Specimen to be tested must contain a minimum of 10 percent tumor.

Transport Temperature

Paraffin embedded Tissue: Room temperature or on ice pack in summer; Slides: Room temperature

Specimen Stability

Paraffin embedded tissue: Room temperature: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable

Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)

Decalcified tissue specimen.

Methodology
Next Generation Sequencing; Fluorescence in situ hybridization; Immunohistochemistry

Setup Schedule

Tuesday

Report Available

10-14 days

Limitations

Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments

Reference Range

An interpretive report will be provided.

Clinical Significance

The Comprehensive LungSEQPlus panel is intended to be used for the detection of somatic alterations within clinically relevant genes in order to help predict response to targeted therapies and prioritize treatment for patients with non-small cell lung cancer. All results should be interpreted in conjunction with other clinical and pathological findings.

Performing Laboratory
med fusion

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.